Edmond DE Rothschild Holding S.A. Has $5.57 Million Position in DexCom, Inc. $DXCM

Edmond DE Rothschild Holding S.A. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4,625.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,800 shares of the medical device company’s stock after purchasing an additional 62,450 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in DexCom were worth $5,569,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares during the last quarter. Avantax Advisory Services Inc. increased its position in shares of DexCom by 42.0% during the first quarter. Avantax Advisory Services Inc. now owns 10,201 shares of the medical device company’s stock valued at $697,000 after buying an additional 3,017 shares during the period. Federated Hermes Inc. raised its position in shares of DexCom by 2,371.4% in the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock worth $136,220,000 after buying an additional 1,914,019 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of DexCom during the 1st quarter valued at about $798,000. Finally, Harvest Fund Management Co. Ltd lifted its position in DexCom by 16.7% during the first quarter. Harvest Fund Management Co. Ltd now owns 30,707 shares of the medical device company’s stock valued at $2,095,000 after purchasing an additional 4,400 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research reports. The Goldman Sachs Group cut their target price on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. Citigroup reduced their price target on DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (d+)” rating on shares of DexCom in a report on Monday. UBS Group cut their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Finally, Evercore ISI assumed coverage on DexCom in a research note on Tuesday. They issued an “in-line” rating and a $68.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.73.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kyle Malady sold 667 shares of the business’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 9,999 shares of company stock valued at $619,391. 0.32% of the stock is currently owned by insiders.

DexCom Price Performance

DXCM opened at $61.69 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market cap of $24.06 billion, a price-to-earnings ratio of 42.84, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The stock has a fifty day simple moving average of $64.93 and a two-hundred day simple moving average of $76.23. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the firm earned $0.45 EPS. The company’s revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.